Endocan's Role in Tumor Growth and Alternative Splicing
Author Information
Author(s): Florence Depontieu, Bogdan-Dragos Grigoriu, Arnaud Scherpereel, Estelle Adam, Maryse Delehedde, Philippe Gosset, Philippe Lassalle
Primary Institution: INSERM U774, Lille, France
Hypothesis
Does the alternative splicing of endocan affect its tumorigenic properties?
Conclusion
The study found that the exon 2 deletion in endocan impairs its tumorigenic properties, suggesting it could be a target for cancer therapies.
Supporting Evidence
- Endocan expression promotes tumor growth in SCID mice.
- EndocanΔ2 does not support tumor growth.
- The exon 2 deletion impairs glycanation of endocan.
- Endocan levels are higher in lung cancer patients.
- EndocanΔ2 is primarily expressed in primates.
Takeaway
Endocan is a protein that helps tumors grow, but when a part of it is missing, it can't help tumors at all.
Methodology
The study involved creating cell lines that overexpressed endocan and its spliced variant, endocanΔ2, and testing their tumorigenic potential in SCID mice.
Limitations
The study was limited to a small sample size of human lung cancer patients and focused on a specific aspect of endocan's function.
Participant Demographics
Nine patients with non-small cell lung cancer (NSCLC) undergoing surgery.
Statistical Information
P-Value
0.022
Statistical Significance
p=0.022
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website